Overall survival (OS) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to lower progression‐free survival (PFS) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · platinum‐sensitive recurrent EOC
Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in progression‐free survival (PFS) compared with PLD alone (low certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to higher overall severe adverse events (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy probably leads to lower hand‐foot syndrome (grade ≥ 3) compared with PLD alone (moderate certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC
Summary of findings 3: PLD with chemotherapy showed no clear difference in neurological (grade ≥ 3) compared with PLD alone (low certainty).
1 finding from 1 review
Quality of life · recurrent platinum‐resistant EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall severe adverse events (grade > 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes overall severe adverse events (grade > 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes anaemia (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes hand‐foot syndrome (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Neurological (grade ≥ 3) · recurrent platinum‐resistant EOC
It is very uncertain whether summary of findings 2: PLD alone changes neurological (grade ≥ 3) compared with other conventional chemotherapy (very low certainty).
1 finding from 1 review
Overall survival (OS) · recurrent platinum‐resistant EOC
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
1 finding from 1 review